Biofrontera Inc
NASDAQ:BFRI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nokian Tyres plc
OTC:NKRKY
|
FI |
|
Zhejiang Natural Outdoor Goods Inc
SSE:605080
|
CN |
Biofrontera Inc
Total Equity
Biofrontera Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biofrontera Inc
NASDAQ:BFRI
|
Total Equity
$10.5m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$81.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$18.5B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$86.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$52.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$26.5B
|
CAGR 3-Years
36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
6%
|
|
Biofrontera Inc
Glance View
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2021-10-14. The firm is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. The company also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.
See Also
What is Biofrontera Inc's Total Equity?
Total Equity
10.5m
USD
Based on the financial report for Dec 31, 2025, Biofrontera Inc's Total Equity amounts to 10.5m USD.
What is Biofrontera Inc's Total Equity growth rate?
Total Equity CAGR 3Y
-24%
Over the last year, the Total Equity growth was 136%. The average annual Total Equity growth rates for Biofrontera Inc have been -24% over the past three years .
